Meiji Seika Pharma Co., Ltd
http://www.meiji-seika-pharma.co.jp/english/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Meiji Seika Pharma Co., Ltd
Asia Deal Watch: ProGen To Partner With Rani On GLP-2 Agonist In Obesity
Plus deals involving Healios/Astellas Institute for Regenerative Medicine, Otsuka/Ionis, IMBiologics/Navigator and more.
Real-World Data: FDA Expounds On Use Of Registries, Challenges In Standardization
Final guidance on assessing registries notes responsibility of sponsors to ensure reliability of data from other organizations and reduce loss of participants to follow-up, while final guidance on data standards for RWD acknowledges sponsors may have limited access to a study’s data sources.
Newron Enters New Year With High Hopes For Evenamide
All being well, the Italian firm will soon have the results from a late-stage study of evenamide in schizophrenia patients who show an inadequate response to atypical antipsychotics.
Products Targeting Alzheimer's, Duchenne & COVID-19 Among New EU Filings
EU marketing authorization applications have been submitted for a number of new drugs, including Eli Lilly’s donanemab, Italfarmaco's givinostat and Arcturus Therapeutics/CSL’s ARCT-154.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Chemo-Sero Therapeutic Research Institute of Japan
- Meiji Holdings
- Meiji Seika Kaisha
- KM Biologics Co., Ltd.
- Kaketsuken
- Romeck Pharma, LLC
- Meiji Pharma USA Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice